In the SURPASS-4 trial, tirzepatide was compared with a different basal insulin, glargine, regarding the achievement of glycaemic control in people with T2D and increased cardiovascular risk being treated with metformin, a sulfonylurea or an SGLT-2 inhibitor. Here, INS is linked to type 2 diabetes mellitus.